Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.
We currently have 22 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.6 billion (IQVIA, June 2018).
We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.
"As we execute our strategy, our focus is to scale up and strengthen our business, so we can deliver sustained financial performance."
Teligent Announces Strategic Review
BUENA, N.J. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Teligent Inc. (Nasdaq: TLGT), a New Jersey -based specialty generic phar...Learn More
Teligent, Inc. Announces Second Quarter 2019 Results
BUENA, N.J. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pha...Learn More
Teligent, Inc. to Hold Conference Call for Second Quarter 2019 Results on Monday August 5th, 2019
BUENA, N.J. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic phar...Learn More